Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Research in context

MLA

Urban Novak, et al. “Combined Therapy with Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance in Relapsed or Refractory Mantle Cell Lymphoma and High-Risk Features: A Phase 1/2 Trial of the European MCL Network (SAKK 36/13)Research in Context.” EClinicalMedicine, vol. 64, no. 102221-, Oct. 2023. EBSCOhost, https://doi.org/10.1016/j.eclinm.2023.102221.

APA

Urban Novak, Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini, Thilo Zander, Georg Hess, Ulrich Mey, Simone Ferrero, Nicolas Mach, Carola Boccomini, Sebastian Böttcher, Michèle Voegeli, Anne Cairoli, Vanesa-Sindi Ivanova, Thomas Menter, Stefan Dirnhofer, Bernhard Scheibe, … Christoph Renner. (2023). Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Research in context. EClinicalMedicine, 64(102221-). https://doi.org/10.1016/j.eclinm.2023.102221

Chicago

Urban Novak, Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini, Thilo Zander, et al. 2023. “Combined Therapy with Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance in Relapsed or Refractory Mantle Cell Lymphoma and High-Risk Features: A Phase 1/2 Trial of the European MCL Network (SAKK 36/13)Research in Context.” EClinicalMedicine 64 (102221-). doi:10.1016/j.eclinm.2023.102221.